Supplementary Data 1 from Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
Samir Zaidi(Memorial Sloan Kettering Cancer Center), Michael J. Morris(Dana-Farber Cancer Institute), Joel Picus(Washington University in St. Louis), Daniel P. Petrylak(Yale University), Tiago Paiva Prudente, Hani M. Babiker, Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Joseph D. Schonhoft, Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Renan E. Aparicio, Oliver Sartor(Mayo Clinic), Ulka N. Vaishampayan(University of Michigan), Don C. Yoo(Brown University), Luisa Fernandez, Richard A. Messmann, Michael Groaning, Phillip H. Kuo(Knowledge Unlatched (Germany))
Cited by 0
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k